Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

PURPOSE: In REVEL, patients with advanced non-small-cell lung cancer (aNSCLC) and patients with increased tumor aggressiveness (rapid disease progression (RDP), platinum-refractory disease (PRD), and high symptom burden (HSB)) benefited from second-line treatment with ramucirumab plus docetaxel over...

Descripción completa

Detalles Bibliográficos
Autores principales: Garon, Edward B., Winfree, Katherine B., Molife, Cliff, Cui, Zhanglin Lin, Arriola, Edurne, Levy, Benjamin, Mekhail, Tarek, Pérol, Maurice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686169/
https://www.ncbi.nlm.nih.gov/pubmed/32318871
http://dx.doi.org/10.1007/s00520-020-05459-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686169/
https://www.ncbi.nlm.nih.gov/pubmed/32318871
http://dx.doi.org/10.1007/s00520-020-05459-0

Ejemplares similares